Thousand Oaks biotech giant Amgen set its sights on the digestive autoimmune disorder known as celiac disease with a $20 million licensing and co-development deal with New Jersey-based Provention Bio. Announced Nov. 5, the partnership will develop an antibody to treat celiac disease that is not responsive to a gluten-free diet, or NRCD. Provention will…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
